Kornimate/medical-research-clean huggingface dataset:
prasterone (dhea) for the treatment of hypoactive sexual desire disorder (hsdd)

Conditions: Hypoactive Sexual Desire Disorder

Summary: the primary objective is to confirm the efficacy of intravaginal prasterone (dhea) on hypoactive sexual desire disorder (hsdd) in postmenopausal women.


Eligibility criteria:
inclusion criteria (main criteria): * postmenopausal women (hysterectomized or not). * women between 40 and 80 years of age. * being in a stable relationship with the opportunity for sexual activity or masturbation at least once a month during the last 6 months or longer (before screening visit) and during the following 8 months. * diagnosis of hsdd confirmed by a qualified clinician. * willing to participate in the study and sign an informed consent. exclusion criteria (main criteria): * chronic or acute life stress or major life change that could have interfered and continues to interfere significantly with sexual activity. * taking drugs which could be responsible for hsdd. * severe medical condition which can explain the loss of sexual desire. * the administration of any investigational drug within 30 days of screening visit. * clinically significant abnormal serum biochemistry, urinalysis or hematology.

Keywords: prasterone dhea menopause sexual disorder
masct-i treatment for advanced solid tumor

Conditions: Solid Tumors

Summary: multiple target antigen stimulating cell therapy (masct-i) is a new immunotherapy that dendritic cells(dc) was induced from autologous peripheral blood. the dc can then be loaded with antigens and re-infused. in vitro, antigen-pulsed dc can stimulate autologous t-cell proliferation and induction of autologous specific cytotoxic t-cells(ctl)，similarly re-infused. the previous research data showed that masct had the modest overall response and less adverse effects for hepatocellular carcinoma patients. the study is aimed to evaluate the safety of masct-1 in patients with advanced solid tumors.

this study is divided into two stages. the first stage is the safety study in small samples, and the second stage is the sample size expansion phase. 40-50 patients with advanced or recurrent solid tumors who had failed after standard treatment will be recruited in this study.

Eligibility criteria:
inclusion criteria: 1. patients with histologically-confirmed, advanced (unresectable) solid tumors（lung cancer, colon cancer, prostate cancer, soft tissue sarcoma, other rare tumor） who have progressed on standard therapy. 2. with written informed consent signed voluntarily by patients themselves. 3. the time of between patients enrollment and the end of other anti-tumors therapies≥1 month. 4. ecog≤2. 5. at least one measurable lesion as defined by recist criteria 1.1 for tumors. 6. life expectancy ≥6 months. 7. with normal cardiopulmonary function. 8. patients have adequate organ function as defined by the following criteria: hemoglobin (hgb) ≥85g/l absolute neutrophil count (anc) ≥1.0×10\^9/l white blood cell (wbc) ≥3.0×10\^9/l platelet count ≥80×10\^9/l alanine aminotransferase (alt) and aspartate aminotransferase (ast) of ≤2.5 upper normal limitation (unl) or ≤5 unl in case of liver metastasis alkaline phosphatase (alp)≤2.5 unl total bilirubin (tbil) of ≤1.5 unl blood urea nitrogen (bun) and creatinine (cr) of≤1.5 unl albumin (alb) ≥30g/l exclusion criteria: 1. pregnant or expecting to pregnant 2. participated in other clinical trials before screening except of observational study. 3. refused to provide blood samples. 4. known allergic history of sodium citrate drugs. 5. known history of organ transplant, including autologous bone marrow transplantation and peripheral stem cell transplantation. 6. known active brain metastases 7. the use of immunosuppressive drugs with current or 14 days before enrollment. 8. active primary immune deficiency. 9. known history of tuberculosis. 10. active infection, including hepatitis b, hepatitis c virus, or human immunodeficiency virus. 11. patients with serious infection, hepatopathy, nephropathy, respiratory disease, cardiovascular disease or incontrollable diabetes, etc. 12. patients have other malignant tumors within 5 years,excluding melanoma and carcinoma in situ of cervix. 13. clinical signs of heart disease. 14. treatment with any anti-tumors agent within 28days of first administration of study treatment. 15. the research on the influence of non legal persons, medical or ethical reasons

Keywords: masct-i solid tumors
using online videos to supplement emergency department discharge instructions

Conditions: Emergency Department Discharge Instructions; Instruction Videos

Summary: this project will evaluate the effectiveness of 38 videos of discharge instructions for patients seen in, and discharged from, the emergency department (ed). the investigators will (1) assess how many ed patients chose view the website, and (2) interview patients who viewed a video, as well as those who didn't view a video (and therefore received standard care), to determine whether patients who viewed a video understood their diagnoses and discharge instructions better.


Eligibility criteria:
inclusion criteria: * age \> 16, or \< 16 and accompanied by a legal guardian * has one of 38 ed discharge diagnoses * fluent in english, or caregiver fluent * has access to a computer, with internet access, in the next 4 days * has access to a telephone exclusion criteria: * age \< 16 when unaccompanied by a legal guardian * decreased level of consciousness at ed discharge (eg palliative patient)
the effect of avocado on cardiovascular disease (cvd) risk factors

Conditions: Cardiovascular Disease; Hyperlipidemia

Summary: the investigators propose to evaluate the effects of avocado consumption (by incorporating 1 unit of fruit per day into a healthy diet) on multiple cardiovascular disease (cvd) risk factors. the investigators will compare chronic consumption of a moderate fat blood cholesterol-lowering diet incorporating one avocado per day versus a blood cholesterol-lowering lower-fat diet on established cvd risk factors including lipids and lipoproteins, and blood pressure (bp). the investigators also will evaluate the effects of an avocado diet on several emerging cvd risk factors. to elucidate the specific benefits of avocado and its accompanying bioactives on the aforementioned risk factors, the investigators will compare the avocado diet with a diet that has the same macronutrient profile (but without the avocado).

a randomized, 3-period cross-over, controlled feeding study was designed to compare the effects of a moderate fat blood cholesterol-lowering diet that provides one avocado per day (total fat = 34% total energy, mufa=18%, sfa \<7%) to an average american diet (aad), lower-fat diet (total fat = 24% total energy, sfa \<7%), and moderate fat diet (with equivalent fatty acid profile to the avocado diet) without avocado. the study population consists of 40 overweight (bmi25-35 kg/m2) men and women with moderately elevated ldl-c, between the25-90th percentiles from nhanes. the investigators hypothesize that a moderate fat heart-healthy diet, including 1 avocado per day will reduce cvd risk factors including lipids, lipoproteins, apolipoproteins, lipoprotein particle size, markers of oxidative stress and inflammation, blood pressure and reverse cholesterol transport compared to an aad, lower-fat diet, and moderate fat diet without avocado.

Eligibility criteria:
inclusion criteria: * healthy non-smoking * overweight (bmi 25-35 kg/m2) men and women * ldl-c between the25-90th percentile from nhanes: 105-194mg/dl for males; 98-190mg/dl for females) exclusion criteria: * bp \>140/90 mmhg; * a history of myocardial infarction, stroke, diabetes mellitus, liver disease, kidney disease, and thyroid disease (unless controlled on medication); * lactation, pregnancy, or desire to become pregnant during the study; * cholesterol-lowering medication use; * intake of putative cholesterol-lowering supplements (psyllium, fish oil capsules, soy lecithin, niacin, fiber, flax, and phytoestrogens, stanol/sterol supplemented foods); * vegetarianism; * nut allergies (other food allergies were reviewed on a case-by-case basis); * refusal to discontinue nutritional supplements, herbs or vitamins

Keywords: cholesterol triglycerides low-density lipoprotein high-density lipoprotein reverse cholesterol transport
chemothetapy forfirinox in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma

Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer

Summary: the purpose of this study is to evaluate the feasibility, efficacy and safety of forfirinox in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

the purpose of this study is to evaluate the feasibility, efficacy and safety of forfirinox in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Eligibility criteria:
inclusion criteria: * • chinese； * stable vital signs, kps≥60; * patients have a diagnosis of advanced or recurrent metastatic extrahepatic cholangiocarcinoma or gallbladder carcinoma by histopathology or cytopathology, who are not suitable for radical surgery or have progressed r1 resection or palliative surgery; * adequate fresh tumor tissue for genome sequencing and immuno- histochemistry test; harboring mutations or abnormal activation of erb-b2 receptor tyrosine kinase signal pathway components; * at least one measurable and evaluable site of disease according to the recist criteria version 1.1; * life expectancy of more than 12 weeks; * adequate hepatic, hematologic and renal functions(alt≤10×upper limit of normal (uln), ast≤10×uln, the child-pugh classification for class a or b, white blood cells≥3×10\^9/l, neutrophils≥1.5×10\^9/l, platelets≥80×10\^9/l , hemoglobin ≥ 90g/l, creatinine clearance rate≥60ml/min; * volunteer for this study, have written informed consent and have good patient compliance; * female patients of childbearing potential and their mates agree to avoid pregnancy. exclusion criteria: * have received following treatment before this study: 1. anti-tumor molecular target therapy; anti-tumor chemotherapy in 6 months; 2. lesions have been treated by irradiation; 3. participate in other therapeutic or interventional clinical trials. - page 5 of 5 \[draft\] - * have central nervous system metastasis; * history of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years; * have symptomatic ascites and need for treatment; * have serious concurrent illness including, but not limited to 1. uncontrolled congestive heart failure(nyha classification grade iii or iv), unstable angina pectoris, unstable cardiac arrhythmias, uncontrolled moderate or serious hypertension(systolic blood pressure \>21.3 kpa or diastolic blood pressure \>13.3 kpa); 2. ongoing or active serious infection; 3. uncontrolled diabetes mellitus; 4. psychiatric illness which potentially hamper the ability to willingly give written informed consent and compliance with the study protocol; 5. hiv infection; 6. other serious illness considered not suitable for this study by investigators. * be allergic or have contraindications to target medicines involved in this study, gemcitabine or oxaliplatin.
to evaluate the safety in patients taking duloxetine for stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: this is an on-going study to evaluate the long-term safety and maintenance of effect of duloxetine in patients suffering with stress urinary incontinence.


Eligibility criteria:
inclusion criteria: have had symptoms of sui for at least 3 months prior to study entry. have urine leakage most often associated with activity (such as coughing, sneezing, exercise). ambulatory and able to use a toilet independently and without difficulty. - exclusion criteria: subjects who participated or were discontinued from any previous studies investigating duloxetine. use of excluded medications within 14 days prior to study entry or at any time during the study. subjects who currently have or have had a history of urogenital cancer.
hypoglycemia associated autonomic failure in type 1 dm, q2

Conditions: Type 1 Diabetes

Summary: alprazolam (xanax) will blunt the body's ability to defend itself from low blood sugar.

due to the fundamental importance of glucose as a cerebral fuel, a complex and redundant counterregulatory response to hypoglycemia exists in man. some studies have shown that prior activation of gaba(a) receptors may result in blunting of counterregulatory responses during next day hypoglycemia. the specific aim is to determine if repeated activation of gaba(a) receptors using alprazolam will result in blunting of neuroendocrine, ans and metabolic counterregulatory mechanisms during next day hypoglycemia in t1dm and healthy man.

Eligibility criteria:
inclusion criteria: * 16 (8 males, 8 females) type 1 diabetes patients aged 18-45 yr. * 16 (8 males, 8 females) healthy controls aged 18-45 yr. * hba1c \> 7.0% (type 1 diabetes patients) * had diabetes for 2-15 years (type 1 diabetes patients) * no clinical evidence of diabetic tissue complications (type 1 diabetes patients) * body mass index 21-30 kg · m-2 * normal bedside autonomic function * normal results of routine blood test to screen for hepatic, renal, and hematological abnormalities * female volunteers of childbearing potential: negative hcg pregnancy test exclusion criteria: * prior history of poor health: any current or prior disease condition that alters carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease * hemoglobin of less than 12 g/dl * abnormal results following screening tests * pregnancy * subjects unable to give voluntary informed consent * subjects with known liver or kidney disease * subjects taking steroids * subjects taking beta blockers * subjects on anticoagulant drugs, anemic, or with known bleeding diseases
transversus thoracis muscle plane block plus rectus sheath block in the perioperative pain management of cardiac surgery

Conditions: Coronary Artery Bypass Grafting or Heart Valve Surgery Via Median Sternotomy

Summary: an emerging regional block technique, transverse thoracic muscle block covers the t2-t6 intercostal nerves and can effectively relieve perioperative pain during median sternotomy. bilateral transverse thoracic muscle plane( ttp) block is expected to be a new analgesic mode in perioperative of cardiac surgery via sternotomy.

this is a single-center, randomized, double-blind, parallel controlled clinical trial. eighty patients planning to undergo coronary artery bypass grafting or heart valve surgery via median sternotomy were randomly assigned 1:1 to the experimental group or control group. after general anesthesia, all subjects were injected with 0.3% ropivacaine (experimental group) or 0.9% normal saline (control group) 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by b-ultrasound by anesthesiologist. the main outcome indicators were the threshold of incision pain and the total amount of analgesics used during the operation and 48h after the operation. secondary outcome measures were as follows: postoperative vas score, duration of mechanical ventilation, days in icu, total days of hospitalization, and hospitalization cost. this study will provide evidence-based medical evidence and clinical data support for the application of ttp block in cardiac surgery.

Eligibility criteria:
inclusion criteria: * patients voluntarily cooperate with the study and sign an informed consent form; * ages between 18 and 65; * american society of anesthesiologists (asa) classification: i-iii; * undergo coronary artery bypass grafting (cabg) or heart valve surgery with midsternal incision. exclusion criteria: * refuse to participate in the trial; * allergic to the anesthetics or analgesics; * suffering with serious systemic diseases (kidney, liver, lungs and endocrine system); * american association of anesthesiologists (asa) classification: iv-v; * unstable hemodynamics; * history of drug abuse or chronic pain; * mental disorders or communication difficulties; * died during or immediately after the operation.
safety and efficacy of tp-03 for the treatment of demodex blepharitis

Conditions: Blepharitis

Summary: the purpose of this study is to compare the safety and efficacy of tp-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to demodex, a microscopic mite frequently found in human hair follicles. the hypothesis for the study is the proportion of participants cured at day 43 with treatment by tp-03, 0.25%, is greater than the proportion cured by treatment with its vehicle.

this phase 2b/3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of tp-03, 0.25%, to vehicle control for the treatment of demodex blepharitis. the primary objective of the study is to assess the safety and efficacy of tp-03 compared to its vehicle from day 1 to day 43 in adult participants with mild to severe demodex blepharitis. the primary efficacy endpoint will be cure based upon collarettes. safety will be determined by assessing adverse effects related to the treatment as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp biomicroscopy and dilated ophthalmoscopy findings.

Eligibility criteria:
inclusion criteria: * be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol * meet all of the following criteria in at least one eye: have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash exclusion criteria: * have used lid hygiene products within 14 days of screening or unwilling to forego the use of lid hygiene products during the study * have worn contact lenses within 7 days of screening or be unwilling to forego contact lens wear during the study * have used artificial eyelashes or eyelash extensions within 7 days of screening or be unwilling to forego their use during the study * pregnancy or lactation

Keywords: demodex
study of azacitidine，venetoclax，and flumatinib in newly diagnosed ph-positive acute leukemia and cml-ap/bp patients

Conditions: Philadelphia Chromosome; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Mixed Phenotype Acute Leukemia

Summary: the purpose of this study is to evaluate the efficacy and safety of azacitidine，venetoclax，and flumatinib in newly diagnosed philadelphia chromosome-positive acute leukemia and accelerated phase or blast phase chronic myeloid leukemia patients.

this is a phase ⅱ, open-label, single-arm, single-center study in newly diagnosed ph-positive acute leukemia and cml-ap/bp patients. the patients will receive azacitidine, venetoclax, and flumatinib regimen in the induction treatment. the patients who respond to induction treatment will undergo consolidation treatment, and an optional allogeneic hematopoietic stem cell transplantation and post-transplantation maintenance treatment with induction therapy according to patient's wishes.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed ph-positive all/aml/mpal and cml-ap/bp without the history of chemotherapy or target therapy. 2. age 18-65. 3. eastern cooperative oncology group (ecog) score: 0-3. 4. total serum bilirubin ≤ 2 x upper limit of normal (uln), alanine aminotransferase (alt) ≤ 1.5 x uln, aspartate aminotransferase (ast) ≤ 1.5 x uln. 5. creatinine clearance ≥ 30 ml/min. 6. serum lipase ≤ 1.5 x uln, amylase =\< 1.5 x uln. 7. no consumption of grapefruit, grapefruit products, seville oranges, or star fruit within 3 days prior to starting venetoclax. 8. provide informed consent. exclusion criteria: 1. patients with another malignant disease. 2. patients has participated in or participating in other clinical trials. 3. patients with uncontrolled active infection. 4. patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade iii/iv cardiovascular dysfunction according to the new york heart association classification. 5. patients with hiv infection, active tuberculosis infection, or active hepatitis b or hepatitis c infection. 6. patients with uncontrolled active bleeding. 7. patients with history of previous chemotherapy or target therapy (except for oral hydroxyurea and/or leukopheresis for lowering white blood cell counts). 8. pregnant and lactating women; patients of childbearing potential should be willing to practice methods of contraception throughout the study period. 9. patients with other commodities that the investigators considered not suitable for the enrollment.

Keywords: ph-positive al cml-ap/bp azacitidine+venetoclax+flumatinib
magnetic resonance enterography in inflammatory bowel diseases

Conditions: Inflammatory Bowel Diseases

Summary: assess the accuracy of magnetic resonance-enterography in predicting the extension, location and characteristics of the small bowel segments affected by crohn's disease\& determine the diagnostic performance of standard mr enterography in detecting colonic inflammation and investigate mr enterography's ability to grade inflammatory activity and detect intestinal extra intestinal manifestations

inflammatory bowel diseases (ibd) are chronic disorders of the gastrointestinal tract with a remitting-relapsing disease pattern. ulcerative colitis (uc) and crohn's disease (cd) represent the two main forms of ibd. in cd inflammation affects various parts of the bowel, separated by unchanged intestinal segments, while in ulcerative colitis enteric involvement is continuous, extending from the rectum throughout the colon. additionally, in crohn's disease the inflammatory process spreads through all layers of the intestinal wall, while in uc only the mucosa and sub mucosa are affected. imaging findings, endoscopic studies and histological data together with clinical assessment, can be used to help distinguish these two forms, determine prognosis, assess disease activity and to inform treatment decision-making. a "treat-to-target" strategy with close monitoring of intestinal inflammation is recommended in inflammatory bowel disease (ibd). ileocolonoscopy (cs) remains the gold-standard for assessing disease activity in ibd but is a relatively invasive procedure and is impossible to repeat in the context of tight monitoring strategies. mre is preferred over computed tomography enterography by most radiologists and gastroenterologists because of the potential for differentiating active inflammation from fibrotic strictures, and due to the lack of exposure to ionizing radiation. this is especially true in children, as the onset of ibd in childhood is a known risk factor for high cumulative exposure to ionizing radiation from imaging. mre furthermore provides a transmural study of bowel loops (oedema, wall thickening, and enhancement post contrast). these features make mre ideally suitable to the ibd population.

Eligibility criteria:
inclusion criteria: * patients with different age groups and both sex are eligible for our prospective study 1. either they had undergone colonoscopy or colonoscopy was planned, and they have been recently diagnosed with ibd. 2. suspected to have disease relapse. exclusion criteria: participants are not eligible for our prospective study if they: 1. have evidence of severe or uncontrolled systemic disease that rendered the individual unsuitable for participation. 2. have contraindications to mre (e.g. allergy to all suitable contrast agents, cardiac pacemaker, severe claustrophobia, an inability to lie flat). 3. had a final diagnosis other than ibd.

Keywords: mre